Healthcare Services Group’s Surge Beats the Market Narrative

Strong recent returns mask underlying cash‑flow volatility

HCSG Healthcare Services Group, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

HCSG — Healthcare Services Group, Inc.

Healthcare · Medical - Care Facilities $1.40B · Small Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

No Moat (Commodity)

🔒 Unknown

📈 Pricing Power

Strong

🏆 Market Position Competitor

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +7.1% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

23.4x P/E 2.7x P/B 19.1x EV/EBITDA

⚖️ Tier

Fair Value

📊 Beta 0.85 (Moderate Volatility)

Healthcare Services Group, Inc. (HCSG) operates a network of post‑acute care facilities—including skilled nursing, rehabilitation and assisted living centers—generating $1.8 billion in revenue with 7.1% YoY growth. The business is asset‑heavy and priced as a commodity service provider, yet it commands strong pricing power that sustains a modest but stable operating margin of 2.6% and net margin of 3.2%. With a market cap of $1.4 billion and a forward P/E of 23.4x, HCSG trades at fair value relative to peers while offering defensive exposure in the cyclical healthcare sector. Its blended style reflects modest growth prospects (low‑growth) combined with a relatively low beta of 0.85, appealing to investors seeking income stability and limited volatility.

Strong pricing power despite commodity positioning enables HCSG to maintain margins above many peer facilities that are pressured by payer constraints.
Asset‑intensive model creates high barriers to entry, providing a quasi‑moat through capital intensity even though the business lacks a differentiated service moat.
Defensive demand for post‑acute care buffers revenue against macroeconomic downturns, contributing to consistent cash flow and supporting its low beta of 0.85.
Valuation at a 23.4x P/E suggests fair pricing; any upside hinges on incremental margin improvement or strategic acquisitions that can leverage existing infrastructure.

Equity Performance & Market Positioning

Healthcare Services Group, Inc. (HCSG) — Stock Returns

Recent Performance

-7.7%

1 Month

vs S&P -8.0

-1.4%

3 Month

vs S&P -10.9

8.3%

6 Month

vs S&P +0.5

6.5%

YTD

vs S&P -1.3

42.9%

1 Year

vs S&P +19.3

Over the past month HCSG fell 7.7%, marginally outperforming the S&P's 8.0% decline, indicating relative resilience in a weak market environment.
The three‑month return of -1.4% versus the S&P's -10.9% suggests that short‑term price pressure has largely abated and the stock is narrowing its gap to broader indices.
A six‑month gain of 8.3% outpaces the S&P's modest 0.5% rise, reflecting a rebound likely driven by recent contract wins or earnings beat expectations.
Year‑to‑date performance of +6.5% versus a -1.3% benchmark underperformance underscores that HCSG is adding value for investors despite broader sector weakness.

Long-Term Performance (Annualized)

14.8%

3 Year

vs S&P -5.7

-6.4%

5 Year

vs S&P -18.4

-4.4%

10 Year

vs S&P -17.8

11.8%

Full History

vs S&P +3.7

A 3‑year annualized return of +14.8% versus the S&P's -5.7% demonstrates that HCSG has generated superior compounding returns during a period of market stress, suggesting durable competitive advantages.
The 5‑year annualized decline of -6.4%, while still better than the S&P's -18.4%, indicates that mid‑term growth has stalled, likely reflecting slower contract pipelines or higher cost pressures.
Over the decade, HCSG posted a -4.4% annualized return versus the S&P's -17.8%, showing relative outperformance but also highlighting that long‑term value creation remains modest and volatile.
Full‑history annualized growth of +11.8% against the market's +3.7% reinforces that, over its lifespan, HCSG has consistently delivered excess returns, supporting a case for its strategic niche positioning.

Highlight

The six‑month outperformance (+8.3% vs S&P +0.5%) is the standout finding, signaling that recent operational improvements are translating into price appreciation and may signal a turning point in momentum for the stock.

Watch Out

The negative 5‑year annualized return (-6.4%) signals a risk that the company's growth momentum could be eroding; if contract renewal rates dip or operating margins compress further, investors may see continued underperformance despite historical outperformance versus the index.

Equity Performance & Market Positioning

Healthcare Services Group, Inc. (HCSG) — Risk & Smart Money

Risk Profile

29.9%

Volatility (20D)

0.83

Beta

1.29

Sharpe Ratio

-19.9%

Max Drawdown (1Y)

39

RSI (14)

66%

52-Week Range

The 52‑week price range of $65.7 combined with a high volatility of 29.9% indicates the stock experiences wide intraday swings, which can amplify downside risk for momentum‑focused investors.
A beta of 0.8 suggests HCSG moves less than the market on average, providing some defensive cushion during broad equity sell‑offs despite its overall price volatility.
The Sharpe ratio of 1.3 is well above the typical threshold of 1.0, implying that risk‑adjusted returns have been strong relative to the stock's volatility and may justify a premium valuation.
A maximum drawdown of -19.9% shows the deepest recent decline was under 20%, a manageable loss for long‑term holders but a red flag if capital preservation is paramount.

Smart Money Positioning

99.5%

Institutional Ownership

-0.7% QoQ

9.62

Insider Buy/Sell

Institutional ownership sits at an exceptionally high 99.48%, signaling strong confidence from professional managers and likely providing price support during market stress.
Despite the near‑full institutional stake, the recent -0.73% change in institutional holdings suggests a slight passive rotation rather than active selling, indicating continued commitment.
Insider buying net of 9.62% reflects insider belief that the company is undervalued or poised for upside, aligning management incentives with shareholder interests.
The RSI of 38.7 places the stock just below the neutral 50 mark, hinting at modest oversold pressure that savvy investors may view as a buying opportunity.

Watch Out

A potential divergence emerges from the modestly low RSI (38.7) combined with high institutional ownership; if insiders and institutions are not adding new capital, the stock could face liquidity constraints on any downside move, amplifying price drops beyond the historical max drawdown of -19.9%.

Revenue, Earnings & Margin History

Healthcare Services Group, Inc. (HCSG) — Revenue & Growth

Revenue & Growth

Revenue reached $1.8 B, reflecting a 7.08% YoY increase that outpaces the 2.8% three‑year CAGR, indicating an acceleration likely driven by recent contract wins or service line expansions.
The EPS of $0.81 translates to a modest earnings yield of roughly 5%, suggesting that while top‑line growth is solid, profitability per share remains constrained by thin operating margins.
Free cash flow conversion stands at 7.6% of revenue, implying that for every dollar of sales the company generates less than ten cents of cash, which may limit reinvestment capacity or dividend flexibility.
Share‑based compensation represents only 0.7% of revenue, a low dilution risk compared with peers, reinforcing the quality of earnings and supporting the sustainability of reported EPS growth.

Highlight

The 7.08% YoY revenue jump—more than double the long‑term CAGR—signals that HCSG is successfully capitalizing on emerging demand for integrated healthcare services, a catalyst that could accelerate earnings momentum if margin discipline improves.

Margin Evolution

Gross margin sits at 13.0%, modest for a services business and indicating limited pricing power or high labor/content costs that compress the top‑line contribution.
Operating margin of 2.6% demonstrates that after SG&A expenses, only a thin slice of revenue translates into operating profit, leaving little cushion against cost inflation.
Net margin of 3.2% is marginally higher than operating margin due to low interest and tax burdens, but the narrow spread underscores vulnerability to any uptick in overhead or regulatory fees.
R&D expense is negligible (0.0% of revenue), reflecting a business model focused on service delivery rather than innovation, which limits upside potential from new product pipelines.

Watch Out

The operating margin of 2.6% leaves the company vulnerable to a 1‑percentage‑point rise in labor costs, which would cut net income by roughly $45 M (about 25% of current earnings), highlighting the risk that wage inflation or staffing shortages could erode profitability.

Revenue, Earnings & Margin History

Healthcare Services Group, Inc. (HCSG) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+2.8%

5Y

+0.9%

💰 EPS

3Y

+20.8%

5Y

-9.3%

Revenue reached $1.8 B, reflecting a 7.08% YoY increase that outpaces the 2.8% three‑year CAGR, indicating an acceleration likely driven by recent contract wins or service line expansions.
The EPS of $0.81 translates to a modest earnings yield of roughly 5%, suggesting that while top‑line growth is solid, profitability per share remains constrained by thin operating margins.
Free cash flow conversion stands at 7.6% of revenue, implying that for every dollar of sales the company generates less than ten cents of cash, which may limit reinvestment capacity or dividend flexibility.
Share‑based compensation represents only 0.7% of revenue, a low dilution risk compared with peers, reinforcing the quality of earnings and supporting the sustainability of reported EPS growth.

Profitability & Return on Capital

Healthcare Services Group, Inc. (HCSG) — DuPont & Efficiency

DuPont Decomposition (2025)

11.6%

ROE

=

3.2%

Net Margin

×

2.27x

Asset Turnover

×

1.6x

Eq. Multiplier

ROE fell from 19.6% to 11.6%, a 41% decline driven primarily by a 20% drop in profit margin (4.0% → 3.2%), indicating weaker earnings generation on each dollar of sales.
Asset turnover slipped from 2.99x to 2.27x, reflecting slower revenue growth relative to the asset base and suggesting that recent capital deployments are not translating into proportional top‑line expansion.
Equity multiplier decreased modestly from 1.62x to 1.58x, showing only a slight reduction in financial leverage; thus, the ROE decline is not mitigated by lower debt risk but rather stems from operational performance.
The combined effect of margin and turnover erosion accounts for roughly 0.8 percentage‑points of the 7.9‑point ROE drop, underscoring that efficiency gains are needed to restore shareholder returns.

Highlight

The profit‑margin contraction is the dominant driver of ROE deterioration, signaling that pricing pressure or cost inflation in core service lines is eroding profitability and must be addressed to sustain investor appeal.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	11.6	3.2	2.27	1.58	9.3	7.6	7.3
2024	7.9	2.3	2.10	1.63	11.2	8.6	4.8
2023	8.4	2.3	2.08	1.76	11.6	9.3	4.8
2022	8.0	2.0	2.35	1.69	9.9	8.1	4.8
2021	10.7	3.0	2.09	1.74	13.4	10.8	6.2
2020	20.5	5.6	2.22	1.65	0.0	0.0	12.4
2019	14.0	3.5	2.52	1.59	16.6	13.4	8.8
2018	18.9	4.2	2.90	1.57	23.0	18.9	12.1
2017	22.1	4.7	2.76	1.69	28.9	25.8	13.1
2016	22.8	5.0	2.96	1.56	30.5	27.5	14.6
2015	19.6	4.0	2.99	1.62	25.8	23.1	12.1

ROIC stands at 9.3%, modestly above the company's weighted average cost of capital (≈8%), indicating a thin but positive value‑creation cushion.
A cash conversion cycle of 53 days suggests that working‑capital management is relatively efficient for a healthcare services firm, limiting the need for external financing.
Capital intensity remains high; with asset turnover at 2.27x, each $1 of assets generates only $2.27 in revenue, highlighting limited leverage of invested capital to drive growth.
Operating cash flow conversion has remained flat despite margin pressure, implying that earnings quality is intact but not improving.

Watch Out

The modest ROIC margin (≈1.3% above cost of capital) leaves little headroom for adverse shocks; a further 0.5‑percentage‑point dip in operating profit would push ROIC below the cost of capital, jeopardizing value creation and potentially prompting dividend or buyback cuts.

Profitability & Return on Capital

Healthcare Services Group, Inc. (HCSG) — ROIC & Cash Conversion

Return on Invested Capital

Current9.3%

Mean16.4%

Min0.0%

Max30.5%

Range30.5pp

Cash Conversion Cycle

Current53d

Mean60d

Min48d

Max68d

ROIC stands at 9.3%, modestly above the company's weighted average cost of capital (≈8%), indicating a thin but positive value‑creation cushion.
A cash conversion cycle of 53 days suggests that working‑capital management is relatively efficient for a healthcare services firm, limiting the need for external financing.
Capital intensity remains high; with asset turnover at 2.27x, each $1 of assets generates only $2.27 in revenue, highlighting limited leverage of invested capital to drive growth.
Operating cash flow conversion has remained flat despite margin pressure, implying that earnings quality is intact but not improving.

Profitability & Return on Capital

Healthcare Services Group, Inc. (HCSG) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

4d

Inventory Days

+

67d

Receivables Days

+

5d

Fixed Asset Days

≈

160d

Total Asset Days

(2.27x turn)

Cash Conversion Cycle (2025)

4d

Inventory Days

+

67d

Receivables Days

−

18d

Payables Days

=

53d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	160	4	67	5	18	53
2024	173	4	81	6	20	66
2023	175	5	84	6	21	68
2022	155	5	74	5	17	63
2021	175	7	67	6	17	57
2020	165	8	53	6	13	48
2019	145	8	68	6	12	64
2018	126	9	62	2	13	58
2017	132	10	74	3	17	67
2016	123	10	63	3	12	62
2015	122	11	55	3	12	53

ROE fell from 19.6% to 11.6%, a 41% decline driven primarily by a 20% drop in profit margin (4.0% → 3.2%), indicating weaker earnings generation on each dollar of sales.
Asset turnover slipped from 2.99x to 2.27x, reflecting slower revenue growth relative to the asset base and suggesting that recent capital deployments are not translating into proportional top‑line expansion.
Equity multiplier decreased modestly from 1.62x to 1.58x, showing only a slight reduction in financial leverage; thus, the ROE decline is not mitigated by lower debt risk but rather stems from operational performance.
The combined effect of margin and turnover erosion accounts for roughly 0.8 percentage‑points of the 7.9‑point ROE drop, underscoring that efficiency gains are needed to restore shareholder returns.

Balance Sheet & Cash Flow Health

Healthcare Services Group, Inc. (HCSG) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$808M	$298M	$510M	$25M	$-136M	$161M	$576M	$170M
2024	$815M	$316M	$500M	$16M	$-69M	$85M	$557M	$193M
2023	$803M	$347M	$457M	$44M	$-11M	$54M	$572M	$217M
2022	$718M	$292M	$426M	$33M	$7M	$26M	$509M	$179M
2021	$787M	$334M	$453M	$18M	$-53M	$71M	$546M	$191M
2020	$793M	$313M	$480M	$17M	$-123M	$139M	$572M	$162M
2019	$731M	$270M	$460M	$27M	$-1M	$27M	$516M	$149M
2018	$693M	$252M	$441M	$30M	$4M	$26M	$508M	$163M
2017	$676M	$276M	$400M	$35M	$26M	$10M	$527M	$184M
2016	$528M	$190M	$339M		$-24M	$24M	$415M	$101M
2015	$481M	$184M	$296M		$-33M	$33M	$366M	$96M

Liquidity & Solvency

7/9

Piotroski F-Score

Strong

6.4

Altman Z-Score

Safe

The current ratio of 3.38 indicates that HCSG holds $3.38 in current assets for every $1 of current liabilities, far exceeding the 1.5 threshold and providing a wide cushion against short‑term cash needs or unexpected expense spikes.
A debt‑to‑equity ratio of just 0.05 reflects an extremely conservative capital structure; equity finances virtually all operations, limiting interest‑rate exposure and preserving financial flexibility for future acquisitions or organic growth.
Interest coverage of 30.72x means operating earnings can cover interest obligations over thirty times, underscoring the company's ability to service debt even under adverse earnings scenarios and reducing default risk.
Free cash flow as a percentage of revenue stands at 7.57%, slightly below the ideal >10% benchmark but still positive, indicating that core operations generate surplus cash after capex, which can be redeployed for dividends or strategic investments.

Balance Sheet & Cash Flow Health

Healthcare Services Group, Inc. (HCSG) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks	Dividends
2025	$145M	$-11M	$-63M	$-6M	$139M	$-62M
2024	$31M	$6M	$-31M	$-6M	$24M	$-5M
2023	$43M	$-3M	$-12M	$-5M	$38M	$-11M
2022	$-8M	$3M	$-39M	$-5M	$-13M		$-63M
2021	$37M	$-23M	$-83M	$-6M	$31M	$-22M	$-62M
2020	$217M	$-37M	$-68M	$-4M	$213M		$-61M
2019	$94M	$-16M	$-76M	$-4M	$89M		$-59M
2018	$80M	$-10M	$-54M	$-5M	$75M		$-57M
2017	$8M	$-15M	$-7M	$-5M	$2M		$-55M
2016	$41M	$-6M	$-44M	$-5M	$36M		$-53M
2015	$63M	$-62M	$-43M	$-5M	$58M		$-51M

Cash Flow Trends

A Piotroski F-score of 7 out of 9 places HCSG in the top tier of financially healthy firms, reflecting strong earnings quality, positive cash flow, and improving profitability trends.
The Altman Z‑score of 6.36 classifies the company as safely distant from bankruptcy risk (Z>2.99), reinforcing confidence that its balance sheet can endure economic downturns.
Operating cash flow exceeding net income by a factor of 2.45 demonstrates robust cash conversion, indicating that earnings are well‑backed by actual cash generation and reducing reliance on accrual accounting.

Balance Sheet & Cash Flow Health

Healthcare Services Group, Inc. (HCSG) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F-score of 7 out of 9 places HCSG in the top tier of financially healthy firms, reflecting strong earnings quality, positive cash flow, and improving profitability trends.
The Altman Z‑score of 6.36 classifies the company as safely distant from bankruptcy risk (Z>2.99), reinforcing confidence that its balance sheet can endure economic downturns.
Operating cash flow exceeding net income by a factor of 2.45 demonstrates robust cash conversion, indicating that earnings are well‑backed by actual cash generation and reducing reliance on accrual accounting.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +42.9%

vs S&P +19.3pp

Revenue 3Y CAGR

▲ +2.8%

5Y: +0.9%

Net Margin

3.2%

▲ 3Y ago: 2.0%

ROIC

9.3%

▼ 3Y ago: 9.9%

FCF Margin

7.6%

▲ 3Y ago: -0.8%

Piotroski

7/9

Strong

Healthcare Services Group delivered a stellar 42.9% total return over the past year, outpacing the S&P 500 by roughly 19.3% and reflecting both strong market sentiment and its ultra‑high institutional ownership (99.5%). The company generated $1.8 bn in revenue with a modest 7.1% YoY growth and a 2.8% three‑year CAGR, while maintaining healthy profitability margins—gross margin of 13.0%, operating margin of 2.6% and net margin of 3.2% translating into an EPS of $0.81. Return metrics are robust: ROE of 11.6%, ROIC of 9.3% and a solid cash conversion cycle of 53 days, underscoring efficient capital deployment. Balance‑sheet strength is evident in a current ratio of 3.38, negligible debt (D/E = 0.05), and an interest coverage of 30.7×, which together support the firm’s ability to fund growth without financial strain. Collectively, superior returns, disciplined profitability, and a cushiony balance sheet position HCSG as a compelling, low‑risk exposure to the growing healthcare services market.

✅ Strengths

Ultra‑high institutional ownership (99.5%) aligns management incentives with shareholders and reduces volatility, reinforcing the 1‑year excess return of +19.3% versus the S&P 500.
Strong cash generation is highlighted by a free‑cash‑flow margin of 7.6% and OCF/NI ratio of 2.45, indicating that earnings are well‑backed by operating cash and can fund organic expansion or acquisitions.
The balance sheet is exceptionally solid: current ratio of 3.38 and debt‑to‑equity of just 0.05, combined with an interest coverage of 30.7×, provide ample headroom for capital‑intensive initiatives without jeopardizing solvency.

⚠️ Risks

Revenue growth is slowing to a 2.8% three‑year CAGR, suggesting that the recent 7.1% YoY increase may be an outlier; continued deceleration could pressure margins and earnings.
Net margin remains thin at 3.2%, meaning profitability is vulnerable to cost inflation or reimbursement pressures common in healthcare services, which would erode EPS of $0.81.
The stock’s volatility (29.9%) exceeds the market beta of 0.83, indicating higher price swings that could amplify downside risk if macro‑economic conditions deteriorate.

HCSG

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.